Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response?

Coskun U., Yamac D., Gulbahar Ö., Sancak B., Karaman N., Ozkan S.

NEOPLASMA, cilt.54, sa.4, ss.348-352, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 54 Sayı: 4
  • Basım Tarihi: 2007
  • Dergi Adı: NEOPLASMA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.348-352
  • Anahtar Kelimeler: locally advanced, breast cancer, neoadjuvant, YKL-40, MMP-2, MMP-9, PROGNOSTIC VALUE, OVARIAN-CANCER, IMMUNOREACTIVE PROTEIN, GENE-EXPRESSION, PLASMA YKL-40, FREE SURVIVAL, MARKER, CYCLOPHOSPHAMIDE, MEMBER, CELLS
  • Gazi Üniversitesi Adresli: Evet

Özet

Serum levels of YKL-40, MMP-2 and MMP-9 in 27 patients with locally advanced breast carcinoma received neoadjuvant chemotherapy were measured. All patients underwent neoadjuvant chemotherapy named as FAC protocol (5-Fluorouracil, Doxorubicin and Cyclophosphamide) with 21 days interval. There was 26,7% decrease in mean serum YKL-40 levels (from 146,4 mu g/ml to 107,3 mu g/ml) in clinically responsive group. This level was almost unchanged in non-responsive group (P > 0, 05). There was 42, 1% decrease in mean serum YKL-40 levels (from 173,1 mu g/ml to 98, 8 mu g/ml) in pathologically responsive group. This decrease was more dramatic in patients with complete pathological response (70, 2%). However, this level was slightly increased in non-responsive group. Changes in serum levels of MMP-2 and MMP-9 were not found to be associated with tumor response. Serum measurement of YKL-40 can be a helpful tool to predict pathological tumor response in breast cancer patients with neoadjuvant chemotherapy but not MMP-2 and MMP-9.